Amlexanox

STARTING AT

0.6

Per Capsule

Amlexanox can enhance energy expenditure by increasing thermogenesis, leading to weight loss, improved insulin sensitivity, and reduced fat accumulation.

ACTIVE INGREDIENTS
Amlexanox
HOW TO USE
Suggested starting dose
Take 25 mg by mouth one to two times daily.
DISCLAIMER
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.

Medicine Information

Potential Benefits

Decreased fat mass
Improved insulin sensitivity and blood glucose regulation
Decreased systemic inflammation
Increased energy expenditure

Treatment Protocol

Legal

Storage Instructions

Warnings

Potential side effects

Rash, itching or stinging of the skin

Inflammation of the lining of the mouth

Nausea

Diarrhea

WARNINGS

Amlexanox should be avoided in patients with compromised immune systems, such as those with chronic conditions like cancer or HIV, or those undergoing immunosuppressive therapy

Manufacturer Info

How It Works

Amlexanox works by inhibiting protein kinases IKKε and TBK1 in the liver. An immediate effect is reduced food intake. However, a more durable effect is the production of the hormone Fibroblast Growth Factor 21 (FGF21), responsible for increased energy expenditure. In both animals and humans, this results in improvements to insulin sensitivity and inflammation, and decreases in blood glucose, fatty liver, and weight.

F.A.Q

Q. How well does it work?

A. Approximately one in three overweight individuals who try amlexanox may respond. Responders typically present with signs of systemic inflammation, oxidative stress, and features of metabolic syndrome. Ideal candidates may include obese patients with poor glycemic control, elevated visceral fat, and increased C-reactive protein (CRP) levels. Combining amlexanox with low-dose naltrexone (LDN) may offer additional synergistic benefits by further addressing inflammation and immune modulation.

References

1. Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, Chenevert TL, Korytnaya E, Neidert AH, Hench R, Rus D, Horowitz JF, Poirier B, Zhao P, Lehmann K, Jain M, Yu R, Liddle C, Ahmadian M, Downes M, Evans RM, Saltiel AR. Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metab. 2017 Jul 5;26(1):157-170.e7. doi: 10.1016/j.cmet.2017.06.006. PMID: 28683283; PMCID: PMC5663294.

2 . Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, Olefsky JM, Saltiel AR. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013 Mar;19(3):313-21. doi: 10.1038/nm.3082. Epub 2013 Feb 10. PMID: 23396211; PMCID: PMC3594079.